Table 5.
Studies on non-endocrine agents as a breast cancer preventive agent.
| Study | Number of women | Median follow up (mo) | Relative Risk of ER positive cancer | Population |
|---|---|---|---|---|
| Fenretinide [37] | 1,739 | 172 | 0.83 (0.67-1.03) | DCIS/Stage I IDCA |
| Bisphosphonates | ||||
| BCNI [38] | 4,039 | N/A | 0.38 (0.28-0.5) | Case-control/records |
| Chlebowski et al. [39] | 154,768 | 93 | 0.70 (0.52-0.94) | WHI Cohort |
| Metformin | ||||
| Bodmer et al. [40] | 22,621 | >5-year use | 0.44 (0.24-0.82) | UK Database |
| Bosco et al. [41] | 4,323 | >1-year use | 0.81 (0.63-0.95) | Case-control 1:10 |
| Tibolone | ||||
| LIFT [42] | 4,538 | 34 | 0.32 (0.13-0.80) | Osteoporosis |
| Statins | ||||
| Browning and Martin [43] | ~17,000 | ~5 years | 1.01 (0.79-1.30) | 7 trials overview |
| Bonovas et al. [44] | - | - | 1.03 (0.93-1.14) | - |
| Baigent et al. [45] | 21,575 | 1.09 (0.79-1.49) | Meta-analysis | - |
| Dale et al. [46] | 33,776 | 1.33 (0.79-2.26) | Meta-analysis | - |
| NSAIDs | ||||
| Zhao et al. [47] | 528,705 | N/A | 0.94 (0.88-1.00) | - |